Zacks Research Brokers Raise Earnings Estimates for TSE:BHC

Bausch Health Companies Inc. (TSE:BHC) – Equities researchers at Zacks Research increased their Q2 2026 earnings per share (EPS) estimates for Bausch Health Companies in a research report issued on Wednesday, March 11th. Zacks Research analyst Team now anticipates that the company will post earnings per share of $1.28 for the quarter, up from their prior forecast of $1.27. The consensus estimate for Bausch Health Companies’ current full-year earnings is $5.55 per share. Zacks Research also issued estimates for Bausch Health Companies’ Q3 2027 earnings at $1.52 EPS and FY2028 earnings at $4.56 EPS.

Several other analysts have also commented on BHC. Raymond James Financial upgraded shares of Bausch Health Companies to a “hold” rating in a research report on Monday, December 15th. Barclays upgraded Bausch Health Companies to a “hold” rating in a research report on Monday, December 8th. Two analysts have rated the stock with a Hold rating, According to data from MarketBeat, Bausch Health Companies currently has a consensus rating of “Hold”.

Bausch Health Companies Stock Performance

Shares of BHC opened at C$6.82 on Friday. Bausch Health Companies has a 12-month low of C$5.91 and a 12-month high of C$11.97. The stock has a market cap of C$2.53 billion, a P/E ratio of 16.24, a PEG ratio of 0.21 and a beta of 0.60. The company has a current ratio of 1.47, a quick ratio of 0.58 and a debt-to-equity ratio of -3,835.02. The company has a 50-day moving average of C$8.50 and a two-hundred day moving average of C$9.05.

Bausch Health Companies (TSE:BHC) last issued its quarterly earnings data on Wednesday, February 18th. The company reported C($0.41) EPS for the quarter. Bausch Health Companies had a net margin of 1.82% and a negative return on equity of 20.27%. The business had revenue of C$6.62 billion during the quarter.

Bausch Health Companies News Summary

Here are the key news stories impacting Bausch Health Companies this week:

• Positive Sentiment: Zacks raised near-term quarterly EPS forecasts: Q3 2027 to $1.52 (from $1.42) and Q2 2026 to $1.28 (from $1.27), signalling some upside in cadence of upcoming quarters that could support short‑term earnings beats. Read More.
• Positive Sentiment: Zacks also lifted Q4 2026 to $1.49 (from $1.46) and Q1 2027 to $1.11 (from $1.09), indicating modestly stronger expected results in several sequential quarters. Read More.
• Neutral Sentiment: Zacks published a FY2028 EPS outlook of $4.56 — useful for long‑term modeling but two years out and unlikely to drive immediate price action. Read More.
• Negative Sentiment: Offsetting the raises, Zacks cut several near‑term and full‑year estimates: Q1 2026 to $1.10 (from $1.13), Q3 2026 to $1.44 (from $1.50) and Q2 2027 to $1.20 (from $1.32), reflecting weaker expected performance in key quarters. Read More.
• Negative Sentiment: Zacks trimmed FY2026 to $5.32 (from $5.37) and cut FY2027 to $5.15 (from $5.30); it also lowered Q4 2027 to $1.32 (from $1.47). Those downward revisions weigh on medium‑term earnings visibility and likely contributed to selling pressure. Read More.

Bausch Health Companies Company Profile

Bausch Health Companies Inc is a global company that develops manufactures and markets a range of pharmaceutical medical device and over-the-counter products primarily in the therapeutic areas of eye health gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. Our approximately 22000 employees are united around our mission of improving peoples lives with our health care products and we manufacture and market health care products directly or indirectly in approximately 100 countries.